Myomo Raises 2025 Revenue Growth Target to 23% to 29%

Myomo, a medical robotics company, has announced an upward revision of its revenue growth target for 2025, setting a new range of 23% to 29%. This adjustment is part of the company's strategy to enhance the quality of potential customers and improve sales conversion rates. The company reported a 28% increase in revenue for the second quarter, and is currently implementing cost-cutting measures to achieve sustainable positive cash flow operations.

The revised revenue growth target for 2025 reflects the company's cautious approach to navigating the changing market conditions and rising costs. The updated guidance is aimed at strengthening operational controls and improving the pipeline conversion rate. This strategic shift underscores the company's commitment to sustainable growth amidst economic uncertainties.

In its second-quarter 2025 financial report, Myomo set its annual revenue guidance for 2025 between 40 million and 42 million USD. This range translates to a growth rate of 23% to 29% compared to the previous year. For the third quarter of 2025, the company anticipates revenue to fall between 9.5 million and 10 million USD. This forecast highlights the company's efforts to enhance its financial performance and adapt to the evolving market landscape.

The company's leadership emphasized the importance of stronger cost management and operational efficiency in the face of market volatility and increasing expenses. This strategic shift is aimed at ensuring that Myomo can continue to deliver value to its stakeholders while maintaining a robust financial position. The revised targets are a clear indication of the company's commitment to navigating the challenges posed by the current economic environment.